Proving treatment efficacy remains a challenge. The lack of a reliable test to monitor treatment efficacy is a major hurdle for developing new drugs for Chagas disease. We are supporting research and raising awareness of the need for ‘biomarkers’ that can be measured with quick and accurate tests.

Boosting immune system’s response to fight infection. We are working to produce an ‘immunomodulator’ that can stimulate the innate immune system to fight the parasitic infection that causes cutaneous leishmaniasis.

New effective, field-adapted drug. Together with Bayer Pharma, we are working to develop emodepside as a new treatment for river blindness with the potential to kill both adult filarial worms and their embryonic larvae, which can cause debilitating and disfiguring clinical symptoms.